爪真菌症市場の評価：治療タイプ・適応症・流通チャネル・地域別の機会および予測 (2017～2031年)

世界の爪真菌症の市場規模は、2024年から2031年の予測期間中にCAGR 5.53％を記録し、2023年の40億1,000万米ドルから、2031年には61億7,000万米ドルの規模に成長すると予測されています。

爪真菌症の市場は、爪真菌症の有病率の高さ、免疫力の低下により爪真菌症に罹患しやすい老齢人口の増加、医療インフラの著しい発展、業界における新製品承認の増加などの要因によって推進されています。爪真菌症の治療には、錠剤、クリーム、スプレー、注射などの抗真菌製剤や、ステロイド、抗生物質などの薬剤クラスが使用されています。

増加する爪真菌症の有病率

世界の爪真菌症の有病率は、加齢、末梢循環不良、糖尿病、運動不足、フットケアを十分に行えないなどの要因により、着実に増加しています。爪の外傷の再発、病原性真菌に長くさらされること、免疫機能の低下、入浴施設の共用なども爪真菌症が蔓延する原因です。さらに、爪の成長が遅く、血液供給が少ないこと、暗くて湿った環境に頻繁に封じ込まれるなどの要因から、爪真菌症は指の爪よりも足の爪に多くみられます。爪真菌症は生命を脅かすものではありませんが、痛みを引き起こし、仕事や社会生活に支障をきたす可能性があるため、公衆衛生上の重要な問題となっています。この疾患の有病率の上昇が、市場における関連製品とサービスの需要を促進しています。

高齢化社会と糖尿病患者の負担

爪真菌症の発生は老齢人口に非常に多く、その理由は免疫系の低下にあります。糖尿病患者は爪甲真菌症の発症に好都合ないくつかの臨床的条件を示し、これには糖化ヘモグロビン (HbA1C) の高値や、爪の肥厚と爪甲病変の加速につながる糖尿病状態の長期化が含まれます。世界の高齢者人口と糖尿病疾患の両方が著しく増加しているため、爪真菌症に対する市場需要も同様に増加し、市場成長がさらに拡大すると予想されています。

CDCが発表したNational Diabetes Statistics Reportによると、成人の糖尿病有病率は年齢とともに増加し、65歳以上では約29.2％に達します。爪真菌症に罹患している人口の20%近くが60歳以上です。糖尿病患者の約3分の1が爪真菌症に罹患している可能性が高いとされています。

アジア太平洋地域が急成長地域へ

アジア太平洋地域はもっとも急成長している地域であると予想されています。これは、高齢者人口の増加、糖尿病およびその他の真菌感染症に関連するリスク因子の有病率の上昇、医療インフラの改善、爪の健康および真菌感染症に対する地域内の意識の高まりといった要因によるものです。同地域における製薬会社の成長や、費用対効果の高い治療オプションのアベイラビリティも同地域の成長に寄与しています。Blueberry Therapeuticsによると、北米における爪真菌症の有病率は約14%であるのに対し、アジア太平洋地域における爪真菌症の有病率は約20%とされています。

当レポートでは、世界の爪真菌症の市場を調査し、市場の定義と概要、市場規模の推移・予測、各種区分・地域別の詳細分析、産業構造、市場成長への影響因子の分析、ケーススタディ、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 調査手法

第2章 プロジェクトの範囲と定義

第3章 エグゼクティブサマリー

第4章 世界の爪真菌症市場の展望

• 市場規模・予測
• 治療タイプ別
  • 薬剤
  • レーザー治療
  • 光線力学療法
• 適応症別
  • 遠位爪下爪真菌症
  • 白色表在性爪真菌症
  • 近位爪下爪真菌症
  • カンジダ性爪真菌症
  • 完全異栄養性爪真菌症
• 流通チャネル別
  • 病院
  • 皮膚科クリニック
  • 小売薬局
  • オンライン薬局
• 地域別
  • 北米
  • 欧州
  • アジア太平洋
  • 南米
  • 中東・アフリカ
• 企業別市場シェア

第5章 世界の爪真菌症市場の展望：地域別

• 北米
• 欧州
• アジア太平洋
• 南米
• 中東・アフリカ

第6章 市場マッピング

• 治療タイプ別
• 適応症別
• 流通チャネル別
• 地域別

第7章 マクロ環境と産業構造

• 需要供給分析
• 輸出入分析
• バリューチェーン分析
• PESTEL分析
• ポーターのファイブフォース分析

第8章 市場力学

• 成長推進因子
• 成長阻害因子 (課題・抑制因子)

第9章 規制の枠組みとイノベーション

• 臨床試験
• 特許の情勢
• 規制当局の承認
• イノベーション/新興技術

第10章 主要企業の情勢

• 市場リーダー上位5社の競合マトリックス
• 市場リーダー上位5社の市場収益分析
• M&A・ジョイントベンチャー (該当する場合)
• SWOT分析 (参入5社)

第11章 価格分析

第12章 ケーススタディ

第13章 主要企業の見通し

• Bausch Health Companies Inc.
• Abbott Laboratories
• Pfizer Inc.
• Bayer AG
• Teva Pharmaceutical Industries Ltd.
• Cipla Inc.
• Merck & Co., Inc.
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• GlaxoSmithKline plc.

第14章 戦略的提言

第15章 当社について・免責事項

List of Tables

• Table 1. Pricing Analysis of Products from Key Players
• Table 2. Competition Matrix of Top 5 Market Leaders
• Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 2. Global Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 3. Global Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 4. Global Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 5. Global Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 6. Global Onychomycosis Market Share (%), By Region, 2017-2031F
• Figure 7. North America Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 8. North America Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 9. North America Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 10. North America Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 11. North America Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 12. North America Onychomycosis Market Share (%), By Country, 2017-2031F
• Figure 13. United States Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 14. United States Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 15. United States Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 16. United States Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 17. United States Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 18. Canada Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 19. Canada Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 20. Canada Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 21. Canada Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 22. Canada Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 23. Mexico Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 24. Mexico Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 25. Mexico Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 26. Mexico Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 27. Mexico Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 28. Europe Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 29. Europe Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 30. Europe Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 31. Europe Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 32. Europe Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 33. Europe Onychomycosis Market Share (%), By Country, 2017-2031F
• Figure 34. Germany Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 35. Germany Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 36. Germany Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 37. Germany Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 38. Germany Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 39. France Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 40. France Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 41. France Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 42. France Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 43. France Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 44. Italy Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 45. Italy Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 46. Italy Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 47. Italy Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 48. Italy Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 49. United Kingdom Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 50. United Kingdom Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 51. United Kingdom Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 52. United Kingdom Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 53. United Kingdom Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 54. Russia Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 55. Russia Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 56. Russia Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 57. Russia Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 58. Russia Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 59. Netherlands Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 60. Netherlands Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 61. Netherlands Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 62. Netherlands Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 63. Netherlands Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 64. Spain Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 65. Spain Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 66. Spain Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 67. Spain Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 68. Spain Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 69. Turkey Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 70. Turkey Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 71. Turkey Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 72. Turkey Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 73. Turkey Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 74. Poland Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 75. Poland Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 76. Poland Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 77. Poland Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 78. Poland Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 79. South America Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 80. South America Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 81. South America Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 82. South America Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 83. South America Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 84. South America Onychomycosis Market Share (%), By Country, 2017-2031F
• Figure 85. Brazil Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 86. Brazil Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 87. Brazil Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 88. Brazil Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 89. Brazil Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 90. Argentina Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 91. Argentina Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 92. Argentina Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 93. Argentina Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 94. Argentina Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 95. Asia-Pacific Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 96. Asia-Pacific Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 97. Asia-Pacific Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 98. Asia-Pacific Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 99. Asia-Pacific Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 100. Asia-Pacific Onychomycosis Market Share (%), By Country, 2017-2031F
• Figure 101. India Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 102. India Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 103. India Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 104. India Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 105. India Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 106. China Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 107. China Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 108. China Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 109. China Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 110. China Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 111. Japan Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 112. Japan Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 113. Japan Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 114. Japan Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 115. Japan Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 116. Australia Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 117. Australia Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 118. Australia Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 119. Australia Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 120. Australia Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 121. Vietnam Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 122. Vietnam Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 123. Vietnam Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 124. Vietnam Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 125. Vietnam Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 126. South Korea Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 127. South Korea Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 128. South Korea Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 129. South Korea Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 130. South Korea Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 131. Indonesia Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 132. Indonesia Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 133. Indonesia Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 134. Indonesia Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 135. Indonesia Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 136. Philippines Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 137. Philippines Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 138. Philippines Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 139. Philippines Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 140. Philippines Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 141. Middle East & Africa Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 142. Middle East & Africa Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 143. Middle East & Africa Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 144. Middle East & Africa Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 145. Middle East & Africa Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 146. Middle East & Africa Onychomycosis Market Share (%), By Country, 2017-2031F
• Figure 147. Saudi Arabia Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 148. Saudi Arabia Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 149. Saudi Arabia Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 150. Saudi Arabia Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 151. Saudi Arabia Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 152. UAE Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 153. UAE Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 154. UAE Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 155. UAE Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 156. UAE Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 157. South Africa Onychomycosis Market, By Value, in USD Billion, 2017-2031F
• Figure 158. South Africa Onychomycosis Market, By Volume, in Million Units, 2017-2031F
• Figure 159. South Africa Onychomycosis Market Share (%), By Treatment Type, 2017-2031F
• Figure 160. South Africa Onychomycosis Market Share (%), By Indication, 2017-2031F
• Figure 161. South Africa Onychomycosis Market Share (%), By Distribution Channel, 2017-2031F
• Figure 162. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 163. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 164. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2023
• Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

Global onychomycosis market is projected to witness a CAGR of 5.53% during the forecast period 2024-2031, growing from USD 4.01 billion in 2023 to USD 6.17 billion in 2031. Onychomycosis market is majorly driven by the high prevalence of onychomycosis, increasing geriatric population that is more prone to such disorders due to the weakened immune system, significant developments in the healthcare infrastructure, and increasing approvals of novel products in the industry. Antifungal preparations like tablets, creams, sprays, and injections, along with other drug classes like steroids and antibiotics, are used for the treatment of onychomycosis. The ability of fungal species to spread quickly through various means like air, water, touch, sharing personal belongings, and using public spaces like swimming pools is the major concern for widespread onychomycosis infection. However, post-COVID awareness about social distancing and growing hygienic practices reduces the risk of onychomycosis and further limit the growth of the market. Additionally, side effects associated with these drugs and therapies and growing antifungal resistance are some major restraints for the market.

In January 2024, Vanda Pharmaceuticals announced that it had received US FDA approval to begin with an investigational new drug (IND) VTR-297, which is a topical antifungal drug candidate for the treatment of onychomycosis. VTR-297 is a histone deacetylase (HDAC) inhibitor with promising antifungal activity against dermatophytes and other fungi. This molecule was originally isolated from the yeast species Streptomyces hygroscopicus as an antifungal antibiotic.

Growing Prevalence of Onychomycosis

The global prevalence of onychomycosis is steadily increasing due to factors such as age, poor peripheral circulation, diabetes, inactivity, and the inability to maintain good foot care. Recurrent nail trauma, longer exposure to pathogenic fungi, suboptimal immune function, and shared bathing facilities are some other reasons for the spread of onychomycosis. Additionally, fungal nail infections are more common in toenails than fingernails due to their slower growth, reduced blood supply, and frequent confinement in dark, moist environments. While onychomycosis is not life-threatening, it can cause pain and potentially undermine work and social lives, making it an important public health problem. The rising prevalence of the disease drives the demand for relevant products and services in the market.

As per an article published in the Journal of Fungi, in May 2023, the global prevalence of onychomycosis was somewhere around 10% and this infection accounted for up to 50% of all nail diseases. Dermatophytes species Trichophyton rubrum and Trichophyton mentagrophytes are common causative agents of onychomycosis, responsible for 60-70% of infections. While yeasts are responsible for approximately 20% of onychomycosis, non-dermatophytes cause the remaining 10%.

Aging Population and Diabetic Disease Burden

The occurrence of onychomycosis is very common in the geriatric population, the reason being the weakened immune system. Diabetic patients present several clinical conditions that favor the development of onychomycosis, including high levels of glycated hemoglobin (HbA1C) and prolonged diabetic status leading to nail thickness and acceleration of nail plate involvement. As the global geriatric population and diabetic disease both are rising significantly, the market demand for onychomycosis is expected to rise as well, further expanding the market growth.

As per the National Diabetes Statistics Report published by the CDC, the prevalence of diabetes in adults increases with age, reaching about 29.2% among those aged 65 years or older. Nearly 20% of the population suffering from onychomycosis is aged above 60 years. Around one-third of diabetic patients are likely to suffer from onychomycosis.

Dominance of Orally Administered Drugs Segment

One of the major onychomycosis market trends is the rising dominance of orally administered drugs over other routes of administration. Orally administered drugs are highly preferred due to their better effectiveness and shorter treatment duration compared to topically applied drugs. Oral antifungal medications like terbinafine and azoles are highly effective treatments for the clinical cure of onychomycosis. They have been found to have higher cure rates compared to topical preparations, which traditionally have low success rates due to the physical hindrance of the nail. Most of the marketed formulations are meant for oral administration only, although a few topical formulations like nail lacquer and sprays also hit the market in recent times.

For instance, in February 2024, Moberg Pharma AB launched MOB-015 under the Terclara brand in partnership with Allderma AB in the Swedish market. The launched drug is witnessing significant traction from the market as it is highly effective against nail fungus and conditions such as onychomycosis. Moberg Pharma estimated the sales potential of MOB-015 at the global level to be around USD 250-500 million.

The Popularity of Distal Subungual Onychomycosis as the Leading Type

Distal subungual onychomycosis is anticipated to be the leading type of onychomycosis occurring among individuals globally since it is the most diagnosed type of onychomycosis. Distal subungual initiates under the edge of the nail or alongside the lateral edges. It is further characterized by the accumulation of debris under the nail, resulting in yellowish, thickened, and brittle toenails. Around 90% of the onychomycosis cases are comprised of distal subungual onychomycosis. Market players are actively designing efficient products for its treatment.

For instance, in November 2023, Blueberry Therapeutics Limited reported that BB2603, a novel topical terbinafine antifungal medication, has demonstrated superiority over placebo (vehicle) with a high degree of statistical significance in the Phase 2b trial (BBTAF202) in patients with onychomycosis, meeting the primary endpoint. 111 participants with mild to moderate distal subungual onychomycosis of the toenail were included in the BBTAF202 European trial. This study evaluated the pharmacokinetics, safety, and effectiveness of BB2603-10 twice daily for three months in comparison to a vehicle, as well as two lower formulation strengths of BB2603-3 and BB2603-1. Successful completion of this trial is anticipated to add another promising product to the market.

Asia-Pacific to be the Fastest-Growing Region

Asia-Pacific is expected to be the fastest-growing region for the onychomycosis market. This is due to factors such as the increasing geriatric population, rising prevalence of diabetes and other risk factors associated with fungal infections, improving healthcare infrastructure, and growing awareness about nail health and fungal infections in the region. The expansion of pharmaceutical companies in the region and the availability of cost-effective treatment options also contribute to the market growth in Asia Pacific. According to Blueberry Therapeutics, the prevalence of onychomycosis in Asia Pacific is around 20%, while in North America, the prevalence of onychomycosis is around 14%.

Future Market Scenario

Terbinafine resistance being the major concern related to onychomycosis treatment needs to be addressed through a shift towards azole-based formulations, which may drive innovation in the future of onychomycosis treatment. Market approval and good marketing strategy for azole-based drugs like Fosravuconazole, Posaconazole, Oteseconazole, and other related compounds is anticipated to expand the market further.

The growing popularity of photodynamic therapy and laser-assisted drug delivery methods have shown high efficacy in the treatment of onychomycosis. The future of the onychomycosis market has promising scope for these treatment options. For instance, according to an article published by 'Mycoses' journal in October 2023, with excellent performance, safety, and tolerability, photodynamic therapy, which uses a cream combining 0.1% w/w FMN or 2% w/w MB with 40% w/w urea, can be a very promising new topical treatment for toenail onychomycosis.

Key Players Landscape and Outlook

Bausch Health Companies Inc., Abbott Laboratories, Pfizer Inc., Bayer AG, Teva Pharmaceutical Industries Ltd., Cipla Inc., Merck & Co., Inc., Novartis AG, Sun Pharmaceutical Industries Ltd., and GlaxoSmithKline plc. are some of the leading players in the onychomycosis market with years of experience and trust. These companies are involved in the development and marketing of drugs, laser therapy, and photodynamic therapy for the treatment of onychomycosis. The key players have active involvement in intellectual property filings and clinical trials, which seems promising for the expansion of the market size.

In October 2023, Bausch Health filed a new patent for the treatment method for nail fungal onychomycosis. The method comprises the application of 10% efinaconazole formulation once a day for 36 weeks without removing the formulation from the nail. The formulation contains ingredients like alcohol, water, and citric acid.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global Onychomycosis Market Outlook, 2017-2031F

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. By Treatment Type
  • 4.2.1. Drugs
    • 4.2.1.1. Topical
    • 4.2.1.2. Oral
  • 4.2.2. Laser Therapy
    • 4.2.2.1. CO2 Ablative Lasers
    • 4.2.2.2. Nd: YAG Lasers
    • 4.2.2.3. Dual-wavelength near-infrared Lasers
  • 4.2.3. Photodynamic Therapy
• 4.3. By Indication
  • 4.3.1. Distal Subungual Onychomycosis
  • 4.3.2. White Superficial Onychomycosis
  • 4.3.3. Proximal Subungual Onychomycosis
  • 4.3.4. Candidal Onychomycosis
  • 4.3.5. Total Dystrophic Onychomycosis
• 4.4. By Distribution Channel
  • 4.4.1. Hospitals
  • 4.4.2. Dermatology Clinics
  • 4.4.3. Retail Pharmacies
  • 4.4.4. Online Pharmacies
• 4.5. By Region
  • 4.5.1. North America
  • 4.5.2. Europe
  • 4.5.3. Asia-Pacific
  • 4.5.4. South America
  • 4.5.5. Middle East and Africa
• 4.6. By Company Market Share (%), 2023

5. Global Onychomycosis Market Outlook, By Region, 2017-2031F

• 5.1. North America*
  • 5.1.1. Market Size & Forecast
    • 5.1.1.1. By Value
    • 5.1.1.2. By Volume
  • 5.1.2. By Treatment Type
    • 5.1.2.1. Drugs
    • 5.1.2.1.1. Topical
    • 5.1.2.1.2. Oral
    • 5.1.2.2. Laser Therapy
    • 5.1.2.2.1. CO2 Ablative Lasers
    • 5.1.2.2.2. Nd: YAG Lasers
    • 5.1.2.2.3. Dual-wavelength near-infrared Lasers
    • 5.1.2.3. Photodynamic Therapy
  • 5.1.3. By Indication
    • 5.1.3.1. Distal Subungual Onychomycosis
    • 5.1.3.2. White Superficial Onychomycosis
    • 5.1.3.3. Proximal Subungual Onychomycosis
    • 5.1.3.4. Candidal Onychomycosis
    • 5.1.3.5. Total Dystrophic Onychomycosis
  • 5.1.4. By Distribution Channel
    • 5.1.4.1. Hospitals
    • 5.1.4.2. Dermatology Clinics
    • 5.1.4.3. Retail Pharmacies
    • 5.1.4.4. Online Pharmacies
  • 5.1.5. United States*
    • 5.1.5.1. Market Size & Forecast
    • 5.1.5.1.1. By Value
    • 5.1.5.1.2. By Volume
    • 5.1.5.2. By Treatment Type
    • 5.1.5.2.1. Drugs
    • 5.1.5.2.1.1. Topical
    • 5.1.5.2.1.2. Oral
    • 5.1.5.2.2. Laser Therapy
    • 5.1.5.2.2.1. CO2 Ablative Lasers
    • 5.1.5.2.2.2. Nd: YAG Lasers
    • 5.1.5.2.2.3. Dual-wavelength near-infrared Lasers
    • 5.1.5.2.3. Photodynamic Therapy
    • 5.1.5.3. By Indication
    • 5.1.5.3.1. Distal Subungual Onychomycosis
    • 5.1.5.3.2. White Superficial Onychomycosis
    • 5.1.5.3.3. Proximal Subungual Onychomycosis
    • 5.1.5.3.4. Candidal Onychomycosis
    • 5.1.5.3.5. Total Dystrophic Onychomycosis
    • 5.1.5.4. By Distribution Channel
    • 5.1.5.4.1. Hospitals
    • 5.1.5.4.2. Dermatology Clinics
    • 5.1.5.4.3. Retail Pharmacies
    • 5.1.5.4.4. Online Pharmacies
  • 5.1.6. Canada
  • 5.1.7. Mexico

All segments will be provided for all regions and countries covered

• 5.2. Europe
  • 5.2.1. Germany
  • 5.2.2. France
  • 5.2.3. Italy
  • 5.2.4. United Kingdom
  • 5.2.5. Russia
  • 5.2.6. Netherlands
  • 5.2.7. Spain
  • 5.2.8. Turkey
  • 5.2.9. Poland
• 5.3. Asia-Pacific
  • 5.3.1. India
  • 5.3.2. China
  • 5.3.3. Japan
  • 5.3.4. Australia
  • 5.3.5. Vietnam
  • 5.3.6. South Korea
  • 5.3.7. Indonesia
  • 5.3.8. Philippines
• 5.4. South America
  • 5.4.1. Brazil
  • 5.4.2. Argentina
• 5.5. Middle East & Africa
  • 5.5.1. Saudi Arabia
  • 5.5.2. UAE
  • 5.5.3. South Africa

6. Market Mapping, 2023

• 6.1. By Treatment Type
• 6.2. By Indication
• 6.3. By Distribution Channel
• 6.4. By Region

7. Macro Environment and Industry Structure

• 7.1. Demand Supply Analysis
• 7.2. Import Export Analysis
• 7.3. Value Chain Analysis
• 7.4. PESTEL Analysis
  • 7.4.1. Political Factors
  • 7.4.2. Economic System
  • 7.4.3. Social Implications
  • 7.4.4. Technological Advancements
  • 7.4.5. Environmental Impacts
  • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
• 7.5. Porter's Five Forces Analysis
  • 7.5.1. Supplier Power
  • 7.5.2. Buyer Power
  • 7.5.3. Substitution Threat
  • 7.5.4. Threat from New Entrant
  • 7.5.5. Competitive Rivalry

8. Market Dynamics

• 8.1. Growth Drivers
• 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

• 9.1. Clinical Trials
• 9.2. Patent Landscape
• 9.3. Regulatory Approvals
• 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

• 10.1. Competition Matrix of Top Five Market Leaders
• 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
• 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
• 10.4. SWOT Analysis (For Five Market Players)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

• 13.1. Bausch Health Companies Inc.
  • 13.1.1. Company Details
  • 13.1.2. Key Management Personnel
  • 13.1.3. Products & Services
  • 13.1.4. Financials (As reported)
  • 13.1.5. Key Market Focus & Geographical Presence
  • 13.1.6. Recent Developments
• 13.2. Abbott Laboratories
• 13.3. Pfizer Inc.
• 13.4. Bayer AG
• 13.5. Teva Pharmaceutical Industries Ltd.
• 13.6. Cipla Inc.
• 13.7. Merck & Co., Inc.
• 13.8. Novartis AG
• 13.9. Sun Pharmaceutical Industries Ltd.
• 13.10. GlaxoSmithKline plc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

14. Strategic Recommendations

15. About Us & Disclaimer